New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 17, 2013
07:47 EDTDSCODiscovery Labs receives new U.S. patent for pulmonary surfactant formulations
Discovery Laboratories announced it has received a patent issued by the United States Patent and Trademark Office entitled "Pulmonary Surfactant Formulations." The claims of the patent provide coverage for synthetic pulmonary surfactant compositions comprising a combination of a proprietary synthetic peptide and various lipids. The patent term expires in December 2028.
News For DSCO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 1, 2016
16:05 EDTDSCODiscovery Labs initiates AEROSURF phase 2b clinical trial
Discovery Labs said that based on the safety and tolerability profile observed to date in the phase 2a clinical program, the company has initiated the AEROSURF phase 2b clinical trial in premature infants 26 to 32 week gestational age receiving nasal continuous positive airway pressure for respiratory distress syndrome. The trial is a multicenter, randomized, controlled study with masked treatment assignment in approximately 240 premature infants and is designed to evaluate the safety and tolerability of aerosolized KL4 surfactant administered in two dose groups, compared to infants receiving nCPAP alone. The following endpoints will be evaluated: time to nCPAP failure, incidence of nCPAP failure and physiological parameters indicating the effectiveness of lung function. The trial is expected to be conducted in up to 60 clinical sites in the United States, Canada, Europe and Latin America. Enrollment is beginning with premature infants 29 to 32 weeks GA, and will include premature infants 26 to 28 weeks GA after completion of the ongoing phase 2a clinical trial in this age group. The xompany anticipates completing enrollment for the phase 2b clinical trial by the end of 2016 and releasing top-line results in the first quarter of 2017. As of December 31, 2015, the xompany had cash and cash equivalents of $38.7M, an amount it anticipates is sufficient to support the AEROSURF phase 2 clinical program and fund operations through Q1 of 2017.
16:03 EDTDSCODiscovery Labs announces resignation of CEO John Cooper
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use